



ZFW

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/538,767 Confirmation No.: 6858
Applicant: Megeney *et al.*
Filed: June 10, 2005
TC/A.AU.: 1623
Examiner: Unassigned

Docket No.: 12399.105001 OHRI US
Customer No.: 20786
Title: Modulation of Stem Cell Differentiation by Modulation of Capase-3 Activity

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450


Transmittal of Information Disclosure Statement

Sir:

The citation of information on the attached Form PTO-1449, "List of Art Cited by Applicant" is made pursuant to 37 C.F.R. §§ 1.56, 1.97, and 1.98. A copy of each listed reference is provided except for U.S./ Patents and U.S. Patent Publications.

Applicant does not believe any fees are due because this paper is submitted before the mailing of a first Office Action on the merits of the application, as under 37 C.F.R. §1.97(b)(3). However, the Commissioner is hereby authorized to charge any fees due or credit any overpayment, to Deposit Account No. 11-0980.


Respectfully submitted,



Madeline I. Johnston, Esq.
Reg. No. 36,174

Dated: March 1, 2006
King & Spalding, LLP
191 Peachtree Street, N.E., Atlanta, GA 30303
Office: (404) 572-4600 / Fax: (404) 572-5145

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in box addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on March 1, 2006.


Diane M. Guilfoyle



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute Form 1449A/PTO

**SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	10/538,767
Filing Date	June 10, 2005
First Named Inventor	Megeney <i>et al.</i>
Group Art Unit	1623
Examiner	Unassigned
Attorney Docket Number	12399.105001 OHR US

4008712 1.DOC

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pgs, Clms, Lns, Where Relevant Passages/Relevant Figs Appear
		Number	Kind Code (if known)			
	AA	3,687,808	A	Merigan, Jr., <i>et al</i>	08-12-1972	
	AB	4,987,071	A	Cech <i>et al.</i>	01-22-1991	
	AC	5,512,438	A	Ecker	04-30-1996	
	AD	5,580,589	A	Stoves <i>et al.</i>	12-03-1996	
	AE	5,641,670	A	Treco <i>et al.</i>	06-24-1997	
	AF	5,728,581	A	Schwartz <i>et al.</i>	03-17-1998	
	AG	5,750,376	A	Weiss <i>et al.</i>	05-12-1998	
	AH	5,981,708	A	Lawman <i>et al.</i>	11-09-1999	
	AI	6,337,184	B1	Miller	01-08-2002	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T 6
		Office ³	Number	Kind Code ² (if known)				
	AJ	WO	03/093487	A1	Victor Chang Card. Res. Inst.	11-13-2003		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 6
	AK	ALAM, A., <i>et al.</i> , "Early activation of caspases during T lymphocyte stimulation results in selective substrate cleavage in nonapoptotic cells," <i>J. Exp. Med.</i> , 190(12):1879-1890 (December 20, 1999).	
	AL	ALTURA, R.A., <i>et al.</i> , "Nuclear expression of Survivin in paediatric ependymomas and choroid plexus tumours correlates with morphologic tumour grade." <i>Br. J. Cancer</i> , 89(9):1743-1749 (November 3, 2003).	
	AM	ASAKURA, A., <i>et al.</i> , "Myogenic specification of side population cells in skeletal muscle," <i>J. Cell Biol.</i> , 159(1):123-134 (October 14, 2002).	
	AN	BEEN, M.D., and CECH, T.R., "One binding site determines sequence specificity of Tetrahymena pre-rRNA self-splicing, trans-splicing, and RNA enzyme activity. <i>Cell</i> , 47(2):207-216 (October 24, 1986).	
	AO	BELIZARIO, J.E., <i>et al.</i> , "Cleavage of caspases-1, -3, -6, -8 and -9 substrates by proteases in skeletal muscles from mice undergoing cancer cachexia," <i>Br. J. Cancer</i> , 84(8):1135-1140 (April 20, 2001).	
	AP	BITKO, V., and BARIK, S., "Phenotypic silencing of cytoplasmic genes using sequence-specific double-stranded short interfering RNA and its application in the reverse genetics of wild type negative-strand RNA viruses," <i>BMC Microbiol.</i> , 1:34 (2001); published electronically December 20, 2001.	

Examiner Signature	Date Con- sidered
-----------------------	----------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Submitted for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application Number	10/538,767
				Filing Date	June 10, 2005
				First Named Inventor	Megeney <i>et al.</i>
				Group Art Unit	1623
				Examiner Name	Unassigned
				Attorney Docket Number	12399.105001 OHR US
Sheet	2	of	6		

4008712 1.DOC

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 6
	BA	BURTON, D.R., <i>et al.</i> , "A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals," <i>Proc. Natl. Acad. Sci. USA</i> , 88(22):10134-10137 (November 15, 1991).	
	BB	CARDONE, M.H., <i>et al.</i> , "The regulation of anoikis: MEKK-1 activation requires cleavage by caspases," <i>Cell</i> , 90(2):315-323 (July 25, 1997).	
	BC	CHAUDHARY, P.M., <i>et al.</i> , "Activation of the c-Jun N-terminal kinase/stress-activated protein kinase pathway by overexpression of caspase-8 and its homologs," <i>J. Biol. Chem.</i> , 274(27):19211-19219 (July 2, 1999).	
	BD	CHENG, T.-C., <i>et al.</i> , "Separable regulatory elements governing myogenin transcription in mouse embryogenesis," <i>Science</i> , 261(5118):215-218 (July 9, 1993).	
	BE	CHOONG, I.C., <i>et al.</i> , "Identification of potent and selective small-molecule inhibitors of caspase-3 through the use of extended tethering and structure-based drug design," <i>J. Med. Chem.</i> , 45(23):5005-5022 (November 7, 2002).	
	BF	COHEN, G.M., "Caspases: the executioners of apoptosis," <i>Biochem. J.</i> , 326 (Pt 1):1-16, (August 15, 1997).	
	BG	COTE, R.J., <i>et al.</i> , "Generation of human monoclonal antibodies reactive with cellular antigens," <i>Proc. Natl. Acad. Sci. USA</i> , 80(7):2026-2030 (April 1983).	
	BH	CREASY, C.L., and CHERNOFF, J., "Cloning and characterization of a human protein kinase with homology to Ste20," <i>J. Biol. Chem.</i> , 270(37):21695-21700 (September 15, 1995).	
	BI	CREGAN, S.P., <i>et al.</i> , "Bax-dependent caspase-3 activation is a key determinant in p53-induced apoptosis in neurons," <i>J. Neurosci.</i> , 19(18):7860-7869 (September 15, 1999).	
	BJ	CUENDA, A., and COHEN, P., "Stress-activated protein kinase-2/p38 and a rapamycin-sensitive pathway are required for C2C12 myogenesis," <i>J. Biol. Chem.</i> , 274(7):4341-4346 (February 12, 1999).	
	BK	DEVEREUX, J., <i>et al.</i> , "A comprehensive set of sequence analysis programs for the VAX," <i>Nucleic Acids Res.</i> , 12(1 Pt 1):387-395 (January 11, 1984).	
	BL	DOUAY, L., "Experimental culture conditions are critical for ex vivo expansion of hematopoietic cells," <i>J. Hematother. Stem Cell Res.</i> , 10(3):341-346 (June 2001).	
	BM	ELBASHIR, S.M., <i>et al.</i> , "Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells," <i>Nature</i> , 411(6836):494-498 (May 24, 2001).	
	BN	FERNANDO, P., <i>et al.</i> , "Caspase 3 activity is required for skeletal muscle differentiation," <i>Proc. Natl. Acad. Sci. USA</i> , 99(17):11025-11030 (August 20, 2002); published electronically August 12, 2002.	
	BO	FRASCH, S.C., <i>et al.</i> , "p38 mitogen-activated protein kinase-dependent and -independent intracellular signal transduction pathways leading to apoptosis in human neutrophils," <i>J. Biol. Chem.</i> , 273(14):8389-8397 (April 3, 1998).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Submitted for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application Number	10/538,767
				Filing Date	June 10, 2005
				First Named Inventor	Megeney <i>et al.</i>
				Group Art Unit	1623
				Examiner Name	Unassigned
Sheet	3	of	6	Attorney Docket Number	12399.105001 OHR US

4008712 1.DOC

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 6
	CA	GALLO, R., <i>et al.</i> , "Distinct effects of Rac1 on differentiation of primary avian myoblasts," <i>Mol. Biol. Cell</i> , 10(10):3137-3150 (October 1999).	
	CB	GARCIA-CALVO, M., <i>et al.</i> , "Inhibition of human caspases by peptide-based and macromolecular inhibitors," <i>J. Biol. Chem.</i> , 273(49):32608-32613 (December 4, 1998).	
	CC	GOODELL, M.A., <i>et al.</i> , "Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo," <i>J. Exp. Med.</i> , 183(4):1797-1806 (April 1, 1996).	
	CD	GRAVES, J.D., <i>et al.</i> , "Caspase-mediated activation and induction of apoptosis by the mammalian Ste20-like kinase Mst1," <i>EMBO J.</i> , 17(8):2224-2234 (April 15, 1998).	
	CE	GRAVES, J.D., <i>et al.</i> , "Both phosphorylation and caspase-mediated cleavage contribute to regulation of the Ste20-like protein kinase Mst1 during CD95/Fas-induced apoptosis," <i>J. Biol. Chem.</i> , 276(18):14909-14915 (May 4, 2001); electronically published February 13, 2001.	
	CF	GRITTI, A., <i>et al.</i> , "Epidermal and fibroblast growth factors behave as mitogenic regulators for a single multipotent stem cell-like population from the subventricular region of the adult mouse forebrain," <i>J. Neurosci.</i> , 19(9):3287-3297 (May 1, 1999).	
	CG	GUSSONI, E., <i>et al.</i> , "Dystrophin expression in the mdx mouse restored by stem cell transplantation," <i>Nature</i> , 401(6751):390-394 (September 23, 1999).	
	CH	HALL, A., and NOBES, C.D., "Rho GTPases: molecular switches that control the organization and dynamics of the actin cytoskeleton," <i>Philos. Trans. R. Soc. Lond. B: Biol. Sci.</i> , 355(1399):965-970 (July 29, 2000).	
	CI	HIERLIHY, A.M., <i>et al.</i> , "The post-natal heart contains a myocardial stem cell population," <i>FEBS Lett.</i> , 530(1-3):239-243 (October 23, 2002).	
	CJ	HITOSHI, S., <i>et al.</i> , "Notch pathway molecules are essential for the maintenance, but not the generation, of mammalian neural stem cells," <i>Genes Dev.</i> , 16(7):846-858 (April 1, 2002).	
	CK	ISHIZAKI, Y., <i>et al.</i> , "A role for caspases in lens fiber differentiation," <i>J. Cell Biol.</i> , 140(1):153-158 (January 12, 1998).	
	CL	JACKSON, K.A., <i>et al.</i> , "Regeneration of ischemic cardiac muscle and vascular endothelium by adult stem cells," <i>J. Clin. Invest.</i> , 107(11):1395-1402 (June 2001).	
	CM	JEFFRIES, A.C., and SYMONS, R.H., "A catalytic 13-mer ribozyme," <i>Nucleic Acids Res.</i> , 17(4):1371-1377 (February 25, 1989).	
	CN	JUO, P., <i>et al.</i> , "Fas activation of the p38 mitogen-activated protein kinase signalling pathway requires ICE/CED-3 family proteases," <i>Mol. Cell. Biol.</i> , 17(1):24-35 (January 1997).	
	CO	KABANOV, A.V., <i>et al.</i> , "A new class of antivirals: antisense oligonucleotides combined with a hydrophobic substituent effectively inhibit influenza virus reproduction and synthesis of virus-specific proteins in MDCK cells," <i>FEBS Lett.</i> , 259(2):327-330 (January 1, 1990).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Submitted for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application Number	10/538,767
				Filing Date	June 10, 2005
				First Named Inventor	Megeney <i>et al.</i>
				Group Art Unit	1623
				Examiner Name	Unassigned
Sheet	4	of	6	Attorney Docket Number	12399.105001 OHR US

4008712 1.DOC

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 6
	DA	KIM, S.-H., and CECH, T.R., <i>et al.</i> , "Three-dimensional model of the active site of the self-splicing rRNA precursor of Tetrahymena," <i>Proc. Natl. Acad. Sci. USA</i> , 84(24):8788-8792 (December 1987).	
	DB	KO, H.W., <i>et al.</i> , "Synergetic activation of p38 mitogen-activated protein kinase and caspase-3-like proteases for execution of calyculin A-induced apoptosis but not N-methyl-D-aspartate-induced necrosis in mouse cortical neurons," <i>J. Neurochem.</i> , 74(6):2455-2461 (June 2000).	
	DC	KÖHLER, G., and MILSTEIN, C., "Continuous cultures of fused cells secreting antibody of predefined specificity," <i>Nature</i> , 256(5517):495-497 (August 7, 1975).	
	DD	KOLODZIEJCZYK, S.M., <i>et al.</i> , "MEF2 is upregulated during cardiac hypertrophy and is required for normal post-natal growth of the myocardium," <i>Curr. Biol.</i> , 9(20):1203-1206 (October 21, 1999).	
	DE	KUIDA, K., <i>et al.</i> , "Decreased apoptosis in the brain and premature lethality in CPP32-deficient mice," <i>Nature</i> , 384(6607):368-372 (November 28, 1996).	
	DF	LECHNER, C., <i>et al.</i> , "ERK6, a mitogen-activated protein kinase involved in C2C12 myoblast differentiation," <i>Proc. Natl. Acad. Sci. USA</i> , 93(9):4355-4359 (April 30, 1996).	
	DG	LETSINGER, R.L., <i>et al.</i> , "Cholesteryl-conjugated oligonucleotides: synthesis, properties, and activity as inhibitors of replication of human immunodeficiency virus in cell culture," <i>Proc. Natl. Acad. Sci. USA</i> , 86(17):6553-6556 (September 1989).	
	DH	MADDOX, D.E., <i>et al.</i> , "Elevated serum levels in human pregnancy of a molecule immunochemically similar to eosinophil granule major basic protein," <i>J. Exp. Med.</i> , 158(4):1211-1226 (October 1, 1983).	
	DI	MADLAMBYAN, G.J., <i>et al.</i> , "Controlling culture dynamics for the expansion of hematopoietic stem cells," <i>J. Hematother. Stem Cell Res.</i> , 10(4):481-492 (August 2001).	
	DJ	MANOHARAN, M., <i>et al.</i> , "Cholic acid-oligonucleotide conjugates for antisense applications," <i>Bioorg. Med. Chem. Lett.</i> , 4(8):1053-1060 (1994).	
	DK	MANOHARAN, M., <i>et al.</i> , "Introduction of a lipophilic thioether tether in the minor groove of nucleic acids for antisense applications," <i>Bioorg. Med. Chem. Lett.</i> , 3(12):2765-2770 (1993).	
	DL	MANOHARAN, M., <i>et al.</i> , "Lipidic nucleic acids," <i>Tet. Lett.</i> , 36(21):3651-3654 (1993).	
	DM	MEGENEY, L.A., <i>et al.</i> , "MyoD is required for myogenic stem cell function in adult skeletal muscle," <i>Genes Dev.</i> , 10(10):1173-1183 (May 15, 1996).	
	DN	MILLS, J.C., <i>et al.</i> , "Apoptotic membrane blebbing is regulated by myosin light chain phosphorylation," <i>J. Cell. Biol.</i> , 140(3):627-636 (February 9, 1998).	
	DO	MINASI, M.G., <i>et al.</i> , "The meso-angioblast: a multipotent, self-renewing cell that originates from the dorsal aorta and differentiates into most mesodermal tissues," <i>Development</i> , 129(11):2773-2784 (June 2002).	
	DP	MOGI, M., and TOGARI, A., "Activation of caspases is required for osteoblastic differentiation," <i>J. Biol. Chem.</i> , 278(48):47477-47482 (November 28, 2003) (Published electronically September 3, 2003).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Submitted for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application Number	10/538,767
				Filing Date	June 10, 2005
				First Named Inventor	Megeney <i>et al.</i>
				Group Art Unit	1623
				Examiner Name	Unassigned
Sheet	5	of	6	Attorney Docket Number	12399.105001 OHR US

4008712 1.DOC

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			T
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	6
	EA	MORRISON, S.L., <i>et al.</i> , "Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains," <i>Proc. Natl. Acad. Sci. USA</i> , 81(21):6851-6855 (November 1984).	
	EB	MUKASA, T., <i>et al.</i> , "Activation of caspase-3 apoptotic pathways in skeletal muscle fibers in laminin alpha2-deficient mice," <i>Biochem. Biophys. Res. Commun.</i> , 260(1):139-142 (June 24, 1999).	
	EC	NEUBERGER, M.S., <i>et al.</i> , "Recombinant antibodies possessing novel effector functions," <i>Nature</i> , 312(5995):604-608 (December 13-19, 1984).	
	ED	OBERHAUSER, B., and WAGNER, E., "Effective incorporation of 2'-O-methyl-oligoribonucleotides into liposomes and enhanced cell association through modification with thiocholesterol," <i>Nucleic Acids Res.</i> , 20(3):533-538 (February 11, 1992).	
	EE	ORLANDI, R., <i>et al.</i> , "Cloning immunoglobulin variable domains for expression by the polymerase chain reaction," <i>Proc. Natl. Acad. Sci. USA</i> , 86(10):3833-3837 (May 1989).	
	EF	ORNATSKY, O.I., <i>et al.</i> , "Post-translational control of the MEF2A transcriptional regulatory protein," <i>Nucleic Acids Res.</i> , 27(13):2646-2654 (July 1, 1999)	
	EG	PEARSON, W.R., and LIPMAN, D.J., "Improved tools for biological sequence comparison," <i>Proc. Natl. Acad. Sci. USA</i> , 85(8):2444-2448 (April 1988).	
	EH	POWELL, W.C., <i>et al.</i> , "The metalloproteinase matrilysin proteolytically generates active soluble Fas ligand and potentiates epithelial cell apoptosis," <i>Curr. Biol.</i> , 9(24):1441-1447 (December 16-30, 1999)	
	EI	QU, G., <i>et al.</i> , "Actin isoform utilization during differentiation and remodeling of BC3H1 myogenic cells," <i>J. Cell. Biochem.</i> , 67(4):514-527 (December 15, 1997).	
	EH	SABOURIN, L.A., and RUDNICKI, M.A., "The molecular regulation of myogenesis," <i>Clin. Genet.</i> 57(1):16-25 (January 2000).	
	EI	SAISON-BEHMOARAS, T., <i>et al.</i> , "Short modified antisense oligonucleotides directed against Ha-ras point mutation induce selective cleavage of the mRNA and inhibit T24 cells proliferation," <i>EMBO J.</i> , 10(5):1111-1118 (May 1991).	
	EJ	SEALE, P., <i>et al.</i> , "Pax7 is required for the specification of myogenic satellite cells," <i>Cell</i> , 102(6):777-786 (September 14, 2000).	
	EK	SHEA, R.G., <i>et al.</i> , "Synthesis, hybridization properties and antiviral activity of lipid-oligodeoxynucleotide conjugates," <i>Nucleic Acids Res.</i> , 18(13):3777-3783 (July 11, 1990).	
	EL	SOMMER, L., and RAO, M., "Neural stem cells and regulation of cell number," <i>Prog. Neurobiol. (Oxford)</i> , 66(1):1-18 (January 2002).	
	EM	SUN, S., and RAVID, K., <i>et al.</i> , "Role of a serine/threonine kinase, Mst1, in megakaryocyte differentiation," <i>J. Cell. Biochem.</i> , 76(1):44-60 (November 1999).	
	EN	TAKEDA, S.-i., <i>et al.</i> , "Construction of chimaeric processed immunoglobulin genes containing mouse variable and human constant region sequences," <i>Nature</i> , 314(6010):452-454 (April 4-10, 1985).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Submitted for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application Number	10/538,767
				Filing Date	June 10, 2005
				First Named Inventor	Megeney <i>et al.</i>
				Group Art Unit	1623
				Examiner Name	Unassigned
Sheet	6	of	6	Attorney Docket Number	12399.105001 OHR US

4008712 I.DOC

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 6
	FA	TEWARI, M., <i>et al.</i> , "Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase," <i>Cell</i> , 81(5):801-809 (June 2, 1995).	
	FB	UTZ, P.J., and ANDERSON, P., <i>et al.</i> , "Life and death decisions: regulation of apoptosis by proteolysis of signaling molecules," <i>Cell Death Differ.</i> , 7(7):589-602 (July 2000).	
	FC	WEIL, M., <i>et al.</i> , "Caspase activation in the terminal differentiation of human epidermal keratinocytes," <i>Curr. Biol.</i> , 9(7):361-364, S1 (29 March 1999).	
	FD	WINTER, G., and MILSTEIN, C., "Man-made antibodies," <i>Nature</i> , 349(6307):293-299 (January 24, 1991).	
	FE	WU, Z., <i>et al.</i> , "p38 and extracellular signal-regulated kinases regulate the myogenic program at multiple steps," <i>Mol. Cell. Biol.</i> , 20(11):3951-3964 (June 2000).	
	FF	YAGAMI-HIROMASA, T., <i>et al.</i> , "A metalloprotease-disintegrin participating in myoblast fusion," <i>Nature</i> , 377(6550):652-656 (October 19, 1995).	
	FG	YANG, S.-H., <i>et al.</i> , "Targeting of p38 mitogen-activated protein kinases to MEF2 transcription factors," <i>Mol. Cell. Biol.</i> , 19(6):4028-4038 (June 1999).	
	FH	YAOITA, Y., and NAKAJIMA, K., "Induction of apoptosis and CPP32 expression by thyroid hormone in a myoblastic cell line derived from tadpole tail," <i>J. Biol. Chem.</i> , 272(8):5122-5127 (February 21, 1997).	
	FI	ZAMORE, P.D., "RNA interference: listening to the sound of silence," <i>Nat. Struct. Biol.</i> , 8(9):746-750 (September 2001).	
	FJ	ZAUG, A.J., <i>et al.</i> , "The Tetrahymena ribozyme acts like an RNA restriction endonuclease," <i>Nature</i> , 324(6096):429-433 (December 4-10, 1986).	
	FK	ZERMATI, Y., <i>et al.</i> , "Caspase activation is required for terminal erythroid differentiation," <i>J. Exp. Med.</i> , 193(2):247-254 (January 15, 2001).	
	FL	ZETSER, A., <i>et al.</i> , "p38 mitogen-activated protein kinase pathway promotes skeletal muscle differentiation. Participation of the Mef2c transcription factor," <i>J. Biol. Chem.</i> , 274(8):5193-5200 (February 19, 1999).	
	FM	ZHENG, T.S., <i>et al.</i> , "Caspase-3 controls both cytoplasmic and nuclear events associated with Fas-mediated apoptosis in vivo," <i>Proc. Natl. Acad. Sci. USA</i> , 95(23):13618-13623 (November 10, 1998).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.